Sue Washer, President and CEO of AGTC, a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic, and central nervous system diseases discusses the gene therapy field, how it works and what she sees as the challenge facing the gene therapy industry and ophthalmology both now and in the near future. She also talks about AGTC’s progress in clinical trials for X-linked Retinitis Pigmentosa (XLRP), an inherited condition that causes progressive vision loss in boys and young men.
Sue Washer is President and CEO of AGTC and brings a decade of experience in pharmaceutical management and research with Abbott Labs and Eli Lilly & Company and more than 26 years of senior management experience with entrepreneurial firms, including three start-ups. At AGTC, she has secured private and public investments of over $290 million for AGTC, negotiated and closed two major collaborations with top Biotech companies resulting in over $150 million of cash in-flows, and led AGTC in efficiently completing critical scientific milestones. She is an appointed member of the Small Business Capital Formation Advisory Committee for the SEC, Associate Vice President of the ECSGB Board of Bio, and currently serves on the Board of Directors of BIO, and BioFlorida. She earned her undergraduate degree in Biochemistry from Michigan State University and her MBA from the University of Florida, where she was one of the first graduates from the Warrington College of Business Entrepreneurship program.